Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
, Klinik für Hämatologie
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
2023 SS
-
2022 WS
-
2018 WS
-
2018 SS
-
2017 WS
-
2017 SS
-
2016 WS
-
2016 SS
-
2015 WS
-
2015 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyIn: European Journal of Nuclear Medicine and Molecular Imaging (2023) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyIn: HemaSphere: Open Access Journal of the European Hematology Association Jg. 7 (2023) Nr. 1, S. E817Online Volltext: dx.doi.org/ (Open Access)
-
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeIn: Blood Cancer Journal Jg. 13 (2023) Nr. 1, 88Online Volltext: dx.doi.org/ (Open Access)
-
CEBPA mutations in 4708 patients with acute myeloid leukemia : differential impact of bZIP and TAD mutations on outcomeIn: Blood Jg. 139 (2022) Nr. 1, S. 87 - 103Online Volltext: dx.doi.org/ (Open Access)
-
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML : Results from a large multicenter studyIn: Blood Advances Jg. 6 (2022) Nr. 5, S. 1394 - 1405Online Volltext: dx.doi.org/ (Open Access)
-
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyIn: Leukemia Jg. 35 (2021) Nr. 3, S. 701 - 711Online Volltext: dx.doi.org/ (Open Access)
-
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide : An international collaborative studyIn: Haematologica / The Hematology Journal Jg. 106 (2021) Nr. 12, S. 3100 - 3106Online Volltext: dx.doi.org/ (Open Access)
-
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaIn: Blood Advances Jg. 5 (2021) Nr. 17, S. 3279 - 3289Online Volltext: dx.doi.org/ (Open Access)
-
Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemiaIn: Cancers Jg. 13 (2021) Nr. 9, S. 2095Online Volltext: dx.doi.org/ (Open Access)
-
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma : the randomized GMMG phase III trial ReLApsEIn: Leukemia Jg. 35 (2021) S. 1134 - 1144Online Volltext: dx.doi.org/
-
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia : Long-term follow-up of the randomized controlled SORAML trialIn: Leukemia Jg. 35 (2021) Nr. 9, S. 2517 - 2525Online Volltext: dx.doi.org/ (Open Access)
-
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?In: Blood Jg. 136 (2020) Nr. 7, S. 823 - 830Online Volltext: dx.doi.org/ (Open Access)
-
EZH2 mutations and impact on clinical outcome : An analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaIn: Haematologica / The Hematology Journal Jg. 105 (2020) Nr. 5, S. E228 - E231Online Volltext: dx.doi.org/ (Open Access)
-
Etoposide combined with FLAG salvage therapy is effective in multiple relapsed / refractory acute myeloid leukemiaIn: Acta Haematologica Jg. 143 (2020) Nr. 5, S. 438 - 445Online Volltext: dx.doi.org/ (Open Access)
-
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemiaIn: Leukemia and Lymphoma Jg. 60 (2019) Nr. 4, S. 1014 - 1022Online Volltext: dx.doi.org/
-
Plerixafor in non-Hodgkin’s lymphoma patients : a German analysis of time, effort and costsIn: Bone Marrow Transplantation Jg. 54 (2019) Nr. 1, S. 123 - 129Online Volltext: dx.doi.org/ (Open Access)
-
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia : results of a phase Ib trialIn: British Journal of Haematology Jg. 185 (2019) Nr. 3, S. 595 - 598Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid LeukemiaIn: Blood Jg. 134 (2019) Nr. Suppl. 1, S. 13Online Volltext: dx.doi.org/ (Open Access)
-
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2) : An open-label, multicentre, phase 2 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 12, S. 1668 - 1679Online Volltext: dx.doi.org/
-
Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma : a multi-center time-motion analysisIn: Bone Marrow Transplantation Jg. 53 (2018) Nr. 3, S. 246 - 254Online Volltext: dx.doi.org/ (Open Access)
-
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients : A subgroup analysis from the phase III trial ReLApsEIn: European Journal of Haematology Jg. 99 (2017) Nr. 1, S. 42 - 50Online Volltext: dx.doi.org/
-
Retrospective analysis of FLAG-idarubicin and FLAG-etoposide as salvage therapies in relapsed/refractory acute myeloid leukemiaIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 43Online Volltext: dx.doi.org/
-
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia : The AML-AZA trial of the Study Alliance LeukemiaIn: Leukemia Jg. 30 (2016) Nr. 3, S. 555 - 561Online Volltext: dx.doi.org/
-
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final Results From a Phase I StudyIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. 10, S. 1104 - 1111Online Volltext: dx.doi.org/
-
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatioIn: BMC Cancer Jg. 16 (2016) S. 290Online Volltext: dx.doi.org/ (Open Access)
-
A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemiaIn: Haematologica Jg. 100 (2015) Nr. Suppl. 1, S. 380 - 380(Open Access)
-
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML) : a multicentre, phase 2, randomised controlled trialIn: The lancet. Oncology Jg. 16 (2015) Nr. 16, S. 1691 - 1699Online Volltext: dx.doi.org/
-
Effiency and toxicity of cyclophasphamide based stem cell mobilization relapsed multiple myeloma patients : Observations from the ongoing phase III trial relapseIn: Haematologica / The Hematology Journal Jg. 100 (2015) Nr. Suppl. 1, S. 258 - 259(Open Access)
-
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsIn: Blood Jg. 126 (2015) Nr. 3, S. 291 - 299Online Volltext: dx.doi.org/
-
Updated results from the soraml trial comparing sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosted acute myeloid leukemiaIn: Haematologica Jg. 100 (2015) Nr. Suppl. 1, S. 318 - 318(Open Access)
-
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia : results from a randomized, placebo-controlled trialIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 25, S. 3110 - 3118Online Volltext: dx.doi.org/
-
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyIn: PLoS ONE Jg. 7 (2012) Nr. 12, S. e52695Online Volltext: dx.doi.org/ (Open Access)
-
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin : a randomized phase II trial in elderly patientsIn: Annals of Oncology Jg. 23 (2012) Nr. 4, S. 990 - 996Online Volltext: dx.doi.org/
-
NK alloreactivity is reduced by GCSF but enhanced by plerixaforIn: Tissue Antigens Jg. 79 (2012) Nr. 6, S. 459 - 460
-
NK alloreactivity is reduced by GCSF but enhanced by plerixaforIn: Bone Marrow Transplantation Jg. 47 (2012) Nr. Suppl. 1, S. 236
-
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure : safety and efficacy data in a series of 21 patients from Europe and the USAIn: Bone Marrow Transplantation Jg. 47 (2012) Nr. 1, S. 18 - 23Online Volltext: dx.doi.org/
-
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II studyIn: Clinical Lymphoma, Myeloma & Leukemia Jg. 11 (2011) Nr. 5, S. 433 - 438Online Volltext: dx.doi.org/
-
CD34-Subpopulations and Clonogenic Progenitors in Mobilized Peripheral Blood Cells from Patients with Acute Myeloid LeukemiaIn: TumorDiagnostik & Therapie Jg. 31 (2010) S. 269 - 275Online Volltext: dx.doi.org/
-
Plerixafor for PBSC mobilization in myeloma patients with advanced renal failure : safety and efficacy data in a series of 12 patients from the US or European Compassionate Use Programmes, and from the US post-licensingIn: Bone Marrow Transplantation Jg. 45 (2010) Nr. Suppl. 2, S. S323 - S324
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.In: Science Jg. 5891 (2008) Nr. 321, S. 974 - 977
-
Health-related quality of life results of the EORTC-GIMEMAGMDS-SG randomized phase III trial AML21 : ten-day decitabine versus standard induction chemotherapy (IC) followed by allografting in older fit patients with acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 46 - 47Online Volltext: dx.doi.org/ (Open Access) -
Single vs double induction with "7+3" containing 60 vs 90 mg daunorubicin for newly diagnosed acute myeloid leukemia : results from the randomized controlled SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 27Online Volltext: dx.doi.org/ (Open Access) -
UBTF Tandem Duplications are Rare but Recurrent Alterations in Adult AML and Associated with Younger Age, Myelodysplasia and Inferior Outcome
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 28Online Volltext: dx.doi.org/ (Open Access) -
10-Day Decitabine Versus Intensive Chemotherapy followed by Transplantation in Fit AML Patients Aged ≥60 Years : Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 1281 - 1283Online Volltext: dx.doi.org/ (Open Access) -
10-Tage Decitabin vs. Standard-Induktion, mit nachfolgender allogener Stammzelltransplantation (HSZT) bei AML-Patienten ≥ 60 Jahre : eine randomisierte Phase III Intergroup-Studie der EORTC Leukemia Group, GIMEMA, CELG und GMDS-SG
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 264Online Volltext: dx.doi.org/ (Open Access) -
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th Annual Meeting, S. 3338 - 3340Online Volltext: dx.doi.org/ (Open Access) -
Metabolic Tumor Volume for Outcome Prediction in Patients with Large B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Treatment
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S211Online Volltext: dx.doi.org/ (Open Access) -
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML : Results from the Randomized Controlled SAL Dauno-Double Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 523 - 525Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Tandem Duplications of the UBTF gene in Adult AML : A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 6262 - 6264Online Volltext: dx.doi.org/ (Open Access) -
Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse : Results of the Second Cohort of the RELAZA2 Trial
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 644Online Volltext: dx.doi.org/ (Open Access) -
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE
17th International Myeloma Workshop ; September 12-15, 2019, Boston, MA, USA,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 19 (2019) Nr. 10, Suppl., S. e286 - e287Online Volltext: dx.doi.org/ -
Antithymocyte Globulin (ATG), CSA and eltrombopag followed by autologous stem cell transplantation in a patient with Very Severe Aplastic Anemia (vSAA) and life-threatening pneumonia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 105Online Volltext: dx.doi.org/ (Open Access) -
Cardiac toxicity of two anthracycline doses in AML induction : Short term results from the randomized SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 8Online Volltext: dx.doi.org/ (Open Access) -
Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients : Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 1461 - 1461Online Volltext: dx.doi.org/ (Open Access) -
EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 1528 - 1528Online Volltext: dx.doi.org/ (Open Access) -
Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 6 - 8Online Volltext: dx.doi.org/ (Open Access) -
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma : Results of the Randomized GMMG Phase III Multicenter Trial Relapse
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1 60th ASH Annual Meeting Abstracts, S. 253 - 253Online Volltext: dx.doi.org/ (Open Access) -
Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 254 - 254Online Volltext: dx.doi.org/ (Open Access) -
The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 9Online Volltext: dx.doi.org/ (Open Access) -
Blinatumomab (CD3/CD19 Bite (R) Antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 190 - 191Online Volltext: dx.doi.org/ -
Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell LymphomaIn: Blood Jg. 118 (2011) Nr. 21, S. 711 - 712Online Volltext: dx.doi.org/
-
Cardiac chloroma in a patient with relapsed acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 85Online Volltext: dx.doi.org/ -
Acquired factor X deficiency in a patient with amyloid light chain amyloidosis
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 247 - 248Online Volltext: dx.doi.org/ -
CD3/CD19 Bispecific Bite (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu G/M-2/D by Continuous infusion is tolerable and results in durable response
15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010,In: Haematologica, the hematology journal Jg. 95 (2010) Nr. Suppl. 2, S. 230 -
CD3/CD19 bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu g/m(2)and day by Continuous Infusion is Tolerable and Results in Durable Responses
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 157Online Volltext: dx.doi.org/ -
Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin : Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid LeukemiaIn: Blood Jg. 116 (2010) Nr. 21, S. 152Online Volltext: dx.doi.org/